QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a single-arm,open-label, prospective, single-center Study of QL1101 and JS001 in
patients with pMMR/MSS refractory metastatic colorectal cancer.
QL1101 is a biosimilar of bevacizumab (Avastin) produced and provided by Qilu Pharmaceutical
Co., Ltd., which has been marketed in China.It's a humanized monoclonal IgG1 antibody
prepared by recombinant DNA technology. By binding to human vascular endothelial growth
factor (VEGF), it inhibits the binding of VEGF to its receptor, blocks the signal
transduction pathway of angiogenesis, and inhibits tumor cell growth. Be produced and
provided by Shanghai Junshi Bioscience Co., Ltd. ,JS001(Tripleitriumab) is the first
China-developed humanized monoclonal antibody against programmed death 1 (PD-1) approved for
marketing in China.
Antiangiogenic drugs combined with PD-1 monoclonal antibodies may reverse the insensitivity
of pMMR/MSS refractory colorectal cancer to PD-1 inhibitors.
The primary objective of this study is to investigate the safety and efficacy of the subjects
who given the combination therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University